The Europe Protein Engineering Market would witness market growth of 15.6% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Protein Engineering Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $512.2 million by 2031. The UK market is exhibiting a CAGR of 14.6% during (2024 - 2031). Additionally, The France market would experience a CAGR of 16.9% during (2024 - 2031).
Protein engineering advancements have been of great benefit to the healthcare industry, which is one of the primary beneficiaries. Therapeutic proteins, including cytokines, monoclonal antibodies, and vaccines, have brought about a paradigm shift in the management of numerous ailments, including infectious diseases, cancer, and autoimmune disorders.
Beyond therapeutic proteins, this engineering is also pivotal in the design of novel diagnostics and biosensors. These engineered proteins can be tailored to recognize specific biomarkers or environmental contaminants, enabling the development of highly sensitive and specific diagnostic tools.
Germany is home to several leading pharmaceutical companies and research institutions investing in this engineering to develop novel therapeutics and diagnostics. According to the Germany Trade & Invest, healthcare spending in Germany exceeded EUR 457 billion in 2021. This growth has partly driven the advancements in the engineering technologies and their application in drug discovery and development. Likewise, In France, the demand for this engineering is driven by increasing investment in research and innovation. The French government has been promoting research and development through initiatives such as the National Research Agency (ANR), which provides funding for innovative research projects. As the first year of implementation for the new three-year ANR Work Programme, 2022 saw the selection of more than 2,000 research projects, with a budget of €1.1 billion, supporting a wide range of research areas, including this engineering. This investment has led to a growing number of research institutions and companies engaged in engineering research. Thus, the demand for this engineering in Europe is driven by expanding research and innovation initiatives, strong pharmaceutical and biotechnology industries, and increasing investment in research and development.
Based on Product, the market is segmented into Instruments, Reagents, and Software & Services. Based on End-use, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic Research Institutes. Based on Technology, the market is segmented into Rational Protein Design, Hybrid Approach, Directed Evolution, De Novo Protein Design, and Others. Based on Protein Type, the market is segmented into Monoclonal Antibodies, Insulin, Vaccines, Growth Factors, Interferon, Colony Stimulating Factors, Coagulation Factors, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Protein Engineering Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $512.2 million by 2031. The UK market is exhibiting a CAGR of 14.6% during (2024 - 2031). Additionally, The France market would experience a CAGR of 16.9% during (2024 - 2031).
Protein engineering advancements have been of great benefit to the healthcare industry, which is one of the primary beneficiaries. Therapeutic proteins, including cytokines, monoclonal antibodies, and vaccines, have brought about a paradigm shift in the management of numerous ailments, including infectious diseases, cancer, and autoimmune disorders.
Beyond therapeutic proteins, this engineering is also pivotal in the design of novel diagnostics and biosensors. These engineered proteins can be tailored to recognize specific biomarkers or environmental contaminants, enabling the development of highly sensitive and specific diagnostic tools.
Germany is home to several leading pharmaceutical companies and research institutions investing in this engineering to develop novel therapeutics and diagnostics. According to the Germany Trade & Invest, healthcare spending in Germany exceeded EUR 457 billion in 2021. This growth has partly driven the advancements in the engineering technologies and their application in drug discovery and development. Likewise, In France, the demand for this engineering is driven by increasing investment in research and innovation. The French government has been promoting research and development through initiatives such as the National Research Agency (ANR), which provides funding for innovative research projects. As the first year of implementation for the new three-year ANR Work Programme, 2022 saw the selection of more than 2,000 research projects, with a budget of €1.1 billion, supporting a wide range of research areas, including this engineering. This investment has led to a growing number of research institutions and companies engaged in engineering research. Thus, the demand for this engineering in Europe is driven by expanding research and innovation initiatives, strong pharmaceutical and biotechnology industries, and increasing investment in research and development.
Based on Product, the market is segmented into Instruments, Reagents, and Software & Services. Based on End-use, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic Research Institutes. Based on Technology, the market is segmented into Rational Protein Design, Hybrid Approach, Directed Evolution, De Novo Protein Design, and Others. Based on Protein Type, the market is segmented into Monoclonal Antibodies, Insulin, Vaccines, Growth Factors, Interferon, Colony Stimulating Factors, Coagulation Factors, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Agilent Technologies, Inc.
- Bruker Corporation
- Thermo Fisher Scientific, Inc.
- Waters Corporation
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- Danaher Corporation
- Genscript Biotech Corporation
- Amgen, Inc.
- Promega Corporation
Market Report Segmentation
By Product- Instruments
- Reagents
- Software & Services
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic Research Institutes
- Rational Protein Design
- Hybrid Approach
- Directed Evolution
- De Novo Protein Design
- Others
- Monoclonal Antibodies
- Insulin
- Vaccines
- Growth Factors
- Interferon
- Colony Stimulating Factors
- Coagulation Factors
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Protein Engineering Market by Product
Chapter 5. Europe Protein Engineering Market by End-use
Chapter 6. Europe Protein Engineering Market by Technology
Chapter 7. Europe Protein Engineering Market by Protein Type
Chapter 8. Europe Protein Engineering Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Agilent Technologies, Inc.
- Bruker Corporation
- Thermo Fisher Scientific, Inc.
- Waters Corporation
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- Danaher Corporation
- Genscript Biotech Corporation
- Amgen, Inc.
- Promega Corporation
Methodology
LOADING...
